- Home
- KLRS vs THTX Comparison
KLRS vs THTX Comparison
Compare KLRS & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- THTX
- Stock Information
- Founded
- KLRS 2019
- THTX 1993
- Country
- KLRS United States
- THTX Canada
- Employees
- KLRS N/A
- THTX N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- THTX Health Care
- Exchange
- KLRS Nasdaq
- THTX Nasdaq
- Market Cap
- KLRS 129.0M
- THTX 119.1M
- IPO Year
- KLRS N/A
- THTX N/A
- Fundamental
- Price
- KLRS $2.61
- THTX $3.15
- Analyst Decision
- KLRS Buy
- THTX Hold
- Analyst Count
- KLRS 1
- THTX 1
- Target Price
- KLRS N/A
- THTX N/A
- AVG Volume (30 Days)
- KLRS 38.9K
- THTX 1.0M
- Earning Date
- KLRS 08-15-2025
- THTX 07-09-2025
- Dividend Yield
- KLRS N/A
- THTX N/A
- EPS Growth
- KLRS N/A
- THTX N/A
- EPS
- KLRS N/A
- THTX N/A
- Revenue
- KLRS N/A
- THTX $84,378,000.00
- Revenue This Year
- KLRS N/A
- THTX N/A
- Revenue Next Year
- KLRS N/A
- THTX $15.13
- P/E Ratio
- KLRS N/A
- THTX N/A
- Revenue Growth
- KLRS N/A
- THTX 2.19
- 52 Week Low
- KLRS $2.28
- THTX $1.12
- 52 Week High
- KLRS $24.15
- THTX $3.20
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- THTX 73.35
- Support Level
- KLRS N/A
- THTX $2.28
- Resistance Level
- KLRS N/A
- THTX $3.20
- Average True Range (ATR)
- KLRS 0.00
- THTX 0.07
- MACD
- KLRS 0.00
- THTX 0.07
- Stochastic Oscillator
- KLRS 0.00
- THTX 94.79
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.